US Patent Issued to Suzhou Suncadia Biopharmaceuticals, Jiangsu Hengrui Medicine, Shanghai Hengrui Pharmaceutical on Oct. 7 for "Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers" (Chinese Inventors)

ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,435,144, issued on Oct. 7, was assigned to Suzhou Suncadia Biopharmaceuticals Co. Ltd. (Jiangsu, China), Jiangsu Hengrui Medicine Co. Ltd. (Jiangsu, China) and Shanghai Hengrui Pharmaceutical Co. Ltd (Shanghai).

"Use of combination of anti-PD-1 antibody and VEGFR inhibitor in preparation of drug for treating cancers" was invented by Xing Sun (Jiangsu, China), Guoqing Cao (Jiangsu, China), Changyong Yang (Jiangsu, China), Lianshan Zhang (Jiangsu, China) and Yong Guo (Jiangsu, China).

According to the abstract* released by the U.S. Patent & Trademark Office: "Disclosed is the use of a combination of an anti-PD-1 antibody and a VEGFR inhibitor in the preparation of a drug for treating ca...